
Catalym
CatalYm GmbH develops innovative immunotherapies that activate the body’s immune system to fight cancer, aiming to improve treatment outcomes and transform the lives of patients worldwide.
About Catalym
Founded in 2016, Catalym is a biotechnology company focused on developing innovative cancer immunotherapies that harness the body’s own immune system to fight tumors. The company specializes in creating antibodies that target a placental factor overexpressed in various cancer types, which plays a key role in suppressing immune responses. By neutralizing this factor, Catalym aims to restore and activate the patient’s immune system to recognize and attack cancer cells more effectively, advancing new treatment options in immuno-oncology.
Recently Added Startups
Meditopia
Meditopia is a global wellbeing platform offering holistic employee assistance solutions, supporting mental and physical health. Founded in 2015, it serves over 40 million users across 15 languages worldwide.
ICAROS
ICAROS develops gamified therapy and training systems that combine immersive gaming with movement science, helping users improve fitness, rehabilitation outcomes, and motivation through engaging, interactive physical activity experiences.
Vuframe
Vuframe® transforms complex CAD data into interactive 3D visualisations and digital twins using gaming technology, helping engineering companies present products faster, more engagingly, and at significantly lower cost.
Related Post

CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding

Top HealthTech Startups in Germany

Startups Hit €125 million+ in 2024 Funding Report
Biotech

Catalym
CatalYm GmbH develops innovative immunotherapies that activate the body’s immune system to fight cancer, aiming to improve treatment outcomes and transform the lives of patients worldwide.

Verovaccines
VEROVACCiNES develops and markets innovative subunit marker vaccines for animal health, offering cost-effective combination vaccines designed to improve disease prevention in livestock.
Germany

Catalym
CatalYm GmbH develops innovative immunotherapies that activate the body’s immune system to fight cancer, aiming to improve treatment outcomes and transform the lives of patients worldwide.

Verovaccines
VEROVACCiNES develops and markets innovative subunit marker vaccines for animal health, offering cost-effective combination vaccines designed to improve disease prevention in livestock.
